Some Anthropic investors want Dario Amodei to soften his AI risk warnings before the IPO, The Information reported.

Shareholders have little influence over him, since Amodei keeps major decisions inside a small circle of co-founders and family.

A board member suggested this year that Anthropic copy the publicity approach of Microsoft and Meta and promote AI in drug discovery.

He reportedly rejected it, arguing that risks to human survival need different handling than ordinary technology marketing.

---

hk01. com/article/60377691